Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01083602 · OUTCOME

Over All Survival

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma · Source last updated 2017-12-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Days
Interval / dispersion
95% Confidence Interval
Time frame
24 weeks

What was measured

Kaplan Meier estimates- median time to event

Analysis population: FAS

Groups in this outcome

Panobinostat + Bortezomib & Dexamethasone

panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Panobinostat + Bortezomib & Dexamethasone55

Reported measurements

Source class 1
Values in Days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Panobinostat + Bortezomib & Dexamethasone559.0Not reported329.0682.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        329.0
        upper Limit
        682.0
        value
        559.0
denoms
  1. counts
    1. group Id
      OG000
      value
      55
    units
    Participants
description
Kaplan Meier estimates- median time to event
dispersion Type
95% Confidence Interval
groups
  1. description
    panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
    id
    OG000
    title
    Panobinostat + Bortezomib & Dexamethasone
param Type
MEDIAN
population Description
FAS
reporting Status
POSTED
time Frame
24 weeks
title
Over All Survival
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice